The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

被引：17
|
作者：
Lonardi, S. [1 ]
Pietrantonio, F. [2 ]
Llavero, N. Tarazona [3 ]
Viladot, C. Montagut [4 ]
Bianchi, A. Sartore [5 ]
Zampino, M. G. [6 ]
Fernandez, M. E. Elez [7 ]
Vivas, C. Santos [8 ]
Mandala, M. [9 ]
Tamberi, S. [10 ]
Sciallero, M. S. [11 ]
Munoz, S. [12 ]
Lazzari, L. [13 ]
Luraghi, P. [13 ]
Torri, V. [14 ]
Cervantes, A.
Bardelli, A. [15 ]
Tabernero, J.
Siena, S.
Marsoni, S. [13 ]
机构：
[1] IOV Ist Oncol Veneto IRCCS, Oncol, Padua, Italy
[2] Fdn IRCCS, Dept Med Oncol, Ist Nazl Tumori, Milan, Italy
[3] Univ Valencia, INCLIVA Biomed Res Inst, Dept Med Oncol, Valencia, Spain
[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[5] Univ Milano La Statale, Dipartimento Oncol Emato Oncol, ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[6] IEO Ist Europeo Oncol, Dept Med Oncol, Milan, Italy
[7] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[8] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Med Oncol Dept, Lhospitalet De Llobregat, Spain
[9] Univ Perugia, Santa Maria Misericordia, Univ Hosp Perugia, Oncol, Perugia, Italy
[10] AUSL Romagna, Osped Infermi, Oncol Unit, Faenza, Ravenna, Italy
[11] IRCCS Osped Policlin San Martino, Med Oncol 1 Dept, Genoa, Italy
[12] Vall Hebron Inst Oncol VHIO, Cellex Ctr, Acad CRO, Barcelona, Spain
[13] IFOM AIRC Inst Mol Oncol, Precis Oncol Unit, Milan, Italy
[14] Ist Ric Farmacol Mario Negri IRCCS, Oncol, Milan, Italy
[15] IFOM AIRC Inst Mol Oncol, Gen Canc & Targeted Therapies, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA28
引用
收藏
页码：S1268 / S1269
页数：2
相关论文
共 50 条
  • [21] Identification of Risk Factors for Recurrence in High-Risk Stage II Colon Cancer
    Hatano, Satoshi
    Ishida, Hideyuki
    Ishibashi, Keiichiro
    Kumamoto, Kensuke
    Haga, Norihiro
    Miura, Ichiro
    INTERNATIONAL SURGERY, 2013, 98 (02) : 114 - 121
  • [22] High-Risk Stage II Colon Cancer After Curative Resection
    Sato, Harunobu
    Maeda, Koutarou
    Sugihara, Kenichi
    Mochizuki, Hidetaka
    Kotake, Kenjiro
    Teramoto, Tetsuo
    Kameoka, Shingo
    Saito, Yukio
    Takahashi, Keiichi
    Hirai, Takashi
    Ohue, Masayuki
    Shirouzu, Kazuo
    Sakai, Yoshiharu
    Watanabe, Toshiaki
    Hirata, Koichi
    Hatakeyama, Katsuyoshi
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (01) : 45 - 52
  • [23] High Expression of CUL9 Is Prognostic and Predictive for Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer
    Zheng, Peng
    Lv, Yang
    Mao, Yihao
    Shen, Feifan
    Zhang, Zhiyuan
    Chang, Jiang
    Yu, Shanchao
    Ji, Meiling
    Feng, Qingyang
    Xu, Jianmin
    CANCERS, 2022, 14 (16)
  • [24] The efficacy of adjuvant chemotherapy for resected high-risk stage II and stage III colorectal cancer in frail patients
    Mima, Kosuke
    Miyanari, Nobutomo
    Kosumi, Keisuke
    Tajiri, Takuya
    Kanemitsu, Kosuke
    Takematsu, Toru
    Inoue, Mitsuhiro
    Mizumoto, Takao
    Kubota, Tatsuo
    Baba, Hideo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (05) : 903 - 912
  • [25] The efficacy of adjuvant chemotherapy for resected high-risk stage II and stage III colorectal cancer in frail patients
    Kosuke Mima
    Nobutomo Miyanari
    Keisuke Kosumi
    Takuya Tajiri
    Kosuke Kanemitsu
    Toru Takematsu
    Mitsuhiro Inoue
    Takao Mizumoto
    Tatsuo Kubota
    Hideo Baba
    International Journal of Clinical Oncology, 2021, 26 : 903 - 912
  • [26] The patient- derived cancer spheroid model predicts response to chemotherapy in curatively resected patients with high-risk stage II and stage III colon cancer
    Mayer, Barbara
    Held, Isabella
    Halfter, Kathrin
    Werner, Jens
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 53 - 53
  • [27] Risk factors for recurrence in patients with high-risk stage II colon cancer after curative resection
    Ohge, H.
    Sadahiro, S.
    Sakamoto, K.
    Tsuchiya, T.
    Takahashi, T.
    Sato, T.
    Kondo, K.
    Ogata, Y.
    Baba, H.
    Itabashi, M.
    Ikeda, M.
    Hamada, M.
    Kusano, M.
    Hyodo, I.
    Sakamoto, J.
    Taguri, M.
    Morita, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S417 - S417
  • [28] Adjuvant Chemotherapy in High-risk Stage II Colon Cancer Patients: (Un) common Practice?
    Koebrugge, B.
    Van Steenbergen, L. N.
    Lips, D. J.
    Lemmens, V. E.
    Van der Linden, H. C.
    Pruijt, H. F.
    Liefers, G.
    Van de Velde, C. J.
    Bosscha, K.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S103 - S103
  • [29] Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer
    Baek, Dong Won
    Kang, Byung Woog
    Lee, Soo Jung
    Kim, Hye Jin
    Park, Su Yeon
    Park, Jun Seok
    Choi, Gyu Seog
    Baek, Jin Ho
    Kim, Jong Gwang
    IN VIVO, 2019, 33 (02): : 649 - 657
  • [30] High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer
    Park, Ji Soo
    Chon, Hong Jae
    Jeung, Hei-Cheul
    Shin, Sang Joon
    Rha, Sun Young
    Ahn, Joong Bae
    Lee, Kang Young
    Kim, Nam Kyu
    Chung, Hyun Cheol
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (09) : 2051 - 2059
12345